Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Non Operating Income: 2009-2024

Historic Other Non Operating Income for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to -$54.9 million.

  • Ligand Pharmaceuticals' Other Non Operating Income rose 108.80% to $833,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 1.66%. This contributed to the annual value of -$54.9 million for FY2024, which is 3126.67% down from last year.
  • According to the latest figures from FY2024, Ligand Pharmaceuticals' Other Non Operating Income is -$54.9 million, which was down 3,126.67% from -$1.7 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Other Non Operating Income ranged from a high of $4.2 million in FY2022 and a low of -$54.9 million during FY2024.
  • Its 3-year average for Other Non Operating Income is -$17.5 million, with a median of -$1.7 million in 2023.
  • In the last 5 years, Ligand Pharmaceuticals' Other Non Operating Income tumbled by 12,438.71% in 2021 and then skyrocketed by 154.73% in 2022.
  • Ligand Pharmaceuticals' Other Non Operating Income (Yearly) stood at $62,000 in 2020, then plummeted by 12,438.71% to -$7.7 million in 2021, then skyrocketed by 154.73% to $4.2 million in 2022, then plummeted by 140.65% to -$1.7 million in 2023, then plummeted by 3,126.67% to -$54.9 million in 2024.